Latest On Carl Zeiss Meditec AG (CZMWF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-03-21 06:00 EST | Dividend | A dividend of $1.1 has been announced on Dec 15, 2023. It will be paid Mar 25, 2024 with an ex-dividend date of Mar 21, 2024. | Neutral |  |
| 2023-05-22 15:56 EST | News | Carl Zeiss Meditec: This MedTech Play Is Still Too Pricey | N/A | |
| 2023-03-23 05:59 EST | Dividend | A dividend of $1.1 has been announced on Dec 23, 2022. It will be paid Mar 27, 2023 with an ex-dividend date of Mar 23, 2023. | Neutral | |
| 2022-11-08 04:33 EST | News | Carl Zeiss Meditec: Buying Opportunity For A Stable Compounding Business | N/A | |
| 2022-08-07 15:10 EST | News | Carl Zeiss Meditec AG (CZMWF) CEO Markus Weber on Q3 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-06 03:18 EST | News | Carl Zeiss Meditec AG 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-03-31 06:02 EST | Dividend | A dividend of $0.9 has been announced on Dec 10, 2021. It will be paid Apr 4, 2022 with an ex-dividend date of Mar 31, 2022. | Neutral | |
| 2021-12-15 02:22 EST | News | Carl Zeiss Meditec AG (CZMWF) CEO Dr. Ludwin Monz on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2021-12-11 02:39 EST | News | Carl Zeiss Meditec AG 2021 Q1 - Results - Earnings Call Presentation | N/A | |
| 2021-12-11 02:39 EST | News | Carl Zeiss Meditec AG (CZMWF) CEO Ludwin Monz on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-03 23:52 EST | News | Carl Zeiss Meditec: Leading Developer Of Ophthalmology And Microsurgery Technology | N/A | |
| 2021-05-28 06:05 EST | Dividend | A dividend of $0.5 has been announced on Dec 15, 2020. It will be paid Jun 1, 2021 with an ex-dividend date of May 28, 2021. | Neutral | |
| 2021-03-18 10:25 EST | Analyst Rating | The Analyst Target Price has decreased from $174.1 to $146. | Neutral | |
| 2021-03-17 22:40 EST | Analyst Rating | The Analyst Target Price has increased from $146 to $174.1. | Buy | |
| 2021-03-17 14:43 EST | Analyst Rating | The Analyst Target Price has decreased from $174.5 to $146. | Neutral | |
| 2021-03-14 10:18 EST | Analyst Rating | The Analyst Target Price has decreased from $174.92 to $174.5. | Neutral | |
| 2021-03-13 09:18 EST | Analyst Rating | The Analyst Target Price has increased from $174.1 to $174.92. | Buy | |
| 2021-03-12 09:12 EST | Analyst Rating | The Analyst Target Price has increased from $173.7 to $174.1. | Buy | |
| 2021-03-11 21:42 EST | Analyst Rating | The Analyst Target Price has increased from $146 to $173.7. | Buy | |
| 2021-03-09 09:16 EST | Analyst Rating | The Analyst Target Price has decreased from $173.87 to $146. | Neutral | |
| 2021-03-08 21:25 EST | Analyst Rating | The Analyst Target Price has increased from $146 to $173.87. | Buy | |
| 2021-03-07 09:17 EST | Analyst Rating | The Analyst Target Price has decreased from $174.72 to $146. | Neutral | |
| 2021-03-06 09:16 EST | Analyst Rating | The Analyst Target Price has decreased from $175.91 to $174.72. | Neutral | |
| 2021-03-05 09:17 EST | Analyst Rating | The Analyst Target Price has decreased from $176.44 to $175.91. | Neutral | |
| 2021-03-04 09:17 EST | Analyst Rating | The Analyst Target Price has increased from $175.9 to $176.44. | Buy | |
| 2021-03-02 21:34 EST | Analyst Rating | The Analyst Target Price has increased from $146 to $175.9. | Buy | |
| 2021-03-01 09:15 EST | Analyst Rating | The Analyst Target Price has decreased from $176.22 to $146. | Neutral | |
| 2021-02-28 09:15 EST | Analyst Rating | The Analyst Target Price has decreased from $177.53 to $176.22. | Neutral | |
| 2021-02-26 21:33 EST | Analyst Rating | The Analyst Target Price has decreased from $177.69 to $177.53. | Neutral | |
| 2021-02-25 22:52 EST | Analyst Rating | The Analyst Target Price has increased from $177.42 to $177.69. | Buy | |
| 2021-02-24 22:58 EST | Analyst Rating | The Analyst Target Price has decreased from $177.62 to $177.42. | Neutral | |
| 2021-02-24 13:05 EST | Analyst Rating | The Analyst Target Price has increased from $177.03 to $177.62. | Buy | |
| 2021-02-23 21:39 EST | Analyst Rating | The Analyst Target Price has increased from $146 to $177.03. | Buy | |
| 2021-02-15 09:07 EST | Analyst Rating | The Analyst Target Price has increased from $0 to $146. | Buy | |
| 2021-02-11 13:03 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-10 23:21 EST | News | Carl Zeiss Meditec AG (CZMWF) CEO Ludwin Monz on 3-Months Quarterly Statement Conference Call 2021 Results - Earnings Call Transcript | N/A | |
| 2021-02-10 09:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-16 13:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-13 13:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-11 15:43 EST | News | Carl Zeiss Meditec AG reports FY results | N/A | |
| 2020-12-11 15:42 EST | News | Carl Zeiss Meditec AG (CZMWF) CEO Ludwin Monz on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2020-12-11 15:42 EST | News | Carl Zeiss Meditec AG 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2020-11-26 22:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-31 07:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-07 10:35 EST | Financials | Company financials have been released. | Neutral | |
About Carl Zeiss Meditec AG (CZMWF):
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, France, Spain, India, the United Kingdom, Turkey, North Africa, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
General
- Name Carl Zeiss Meditec AG
- Symbol CZMWF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- Full Time Employees 3,290
- Fiscal Year EndSeptember
- Web URLhttp://www.zeiss.de/meditec-ag/home.html
View More
Valuation
- Trailing PE 91.07
- Forward PE 58.48
- Price/Sales (Trailing 12 Mt.) 8.42
- Price/Book (Most Recent Quarter) 7.88
- Enterprise Value Revenue 10.17
- Enterprise Value EBITDA 62.77
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 10%
- Return on Assets 5%
- Return on Equity 9%
- Earnings Per Share $1.65
- Revenue Per Share $0
- Gross Profit 745.52 million
- Quarterly Earnings Growth -0.2%
View More
Highlights
- Market Capitalization 13.51 billion
- PEG Ratio 3.19
- Analyst Target Price $146
- Book Value Per Share $16.85
View More
Share Statistics
- Shares Outstanding 89.44 million
- Shares Float 36.55 million
- % Held by Insiders 5909%
- % Held by Institutions 26.19%
View More
Technicals
- Beta 0.18
- 52 Week High $154.3
- 52 Week Low $85
- 50 Day Moving Average 141.97
- 200 Day Moving Average 128.52
View More
Dividends
- Forward Annual Dividend Rate $0.61
- Forward Annual Dividend Yield 0.4%
- Payout Ratio 101%
- Dividend Date 2017-06-02
- ExDividend Date 2021-05-28
- Dividend Per Share $0.64
- Dividend Yield 0%
View More
Carl Zeiss Meditec AG (CZMWF) Dividend Calendar:
CZMWF's last dividend payment was made to shareholders on June 2, 2017.
Carl Zeiss Meditec AG pays out 101% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Carl Zeiss Meditec AG (CZMWF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $0.64 | ||
| 2020-06-30 | 2020-09-30 | $252.97 million | $0.71 | ||
| 2020-03-31 | 2020-06-30 | $345.26 million | $0.07 | $0.40 | -83.4% |
| 2019-12-31 | 2020-03-31 | $414.51 million | $0.31 | $0.40 | -22.85% |
| 2019-09-30 | 2019-12-31 | $470.54 million | $0.48 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $406.75 million | $0.62 | ||
| 2019-03-31 | 2019-06-30 | $385.22 million | $0.65 | ||
| 2018-12-31 | 2019-03-31 | $371.19 million | $0.37 | $0.36 | 2.83% |
| 2018-09-30 | 2018-12-31 | $410.47 million | $0.37 | $0.53 | -30.83% |
| 2018-06-30 | 2018-09-30 | $363.83 million | $0.57 | $0.33 | 72.85% |
| 2018-03-31 | 2018-06-30 | $392.36 million | $0.34 | $0.38 | -9.87% |
| 2017-12-31 | 2018-03-31 | $353.91 million | $0.38 | $0.31 | 23.19% |
| 2017-09-30 | 2017-12-31 | $381.55 million | $0.38 | ||
| 2017-06-30 | 2017-09-30 | $277.21 million | $0.55 | $0.34 | 61.88% |
| 2017-03-31 | 2017-06-30 | $307.49 million | $0.40 | ||
| 2016-12-31 | 2017-03-31 | $280 million | $0.41 | $0.37 | 9.57% |
| 2016-09-30 | 2016-12-31 | $0.40 | $0.37 | 8.11% | |
| 2016-06-30 | 2016-09-30 | $0.43 | $0.30 | 42.53% | |
| 2016-03-31 | 2016-06-30 | $0.27 | $0.31 | -14.03% | |
| 2015-12-31 | 2016-03-31 | $0.43 | $0.23 | 88.17% | |
| 2015-09-30 | 2015-12-31 | $0.23 | |||
| 2015-06-30 | 2015-09-30 | $0.14 | |||
| 2015-03-31 | 2015-06-30 | $0.30 | $0.29 | 3.72% | |
| 2014-12-31 | 2015-03-31 | $0.15 | |||
| 2014-09-30 | 2014-12-31 | $0.28 | $0.30 | -7.2% | |
| 2014-06-30 | 2014-09-30 | $0.27 | $0.27 | -0.81% | |
| 2014-03-31 | 2014-06-30 | $0.30 | $0.35 | -13.94% | |
| 2013-12-31 | 2014-03-31 | $0.33 | |||
| 2013-09-30 | 2013-12-31 | $0.34 | $0.43 | -19.93% | |
| 2013-06-30 | 2013-09-30 | $0.42 | |||
| 2013-03-31 | 2013-06-30 | $0.39 | |||
| 2012-12-31 | 2013-03-31 | $0.31 | |||
| 2012-09-30 | 2012-12-31 | $0.38 | |||
| 2012-06-30 | 2012-09-30 | $0.30 | |||
| 2012-03-31 | 2012-06-30 | $0.22 | |||
| 2011-12-31 | 2012-03-31 | $0.37 | |||
| 2011-09-30 | 2011-12-31 | $0.27 | |||
| 2011-06-30 | 2011-09-30 | $0.30 | |||
| 2011-03-31 | 2011-06-30 | $0.29 | |||
| 2010-12-31 | 2011-03-31 | $0.33 | |||
| 2010-09-30 | 2010-12-31 | $0.23 | $0.00 | ||
| 2010-03-31 | 2010-03-31 | $0.18 | |||
| 2009-12-31 | 2009-12-31 | $0.21 | |||
| 2009-09-30 | 2009-09-30 | $0.32 | |||
| 2009-06-30 | 2009-06-30 | $0.15 | |||
| 2009-03-31 | 2009-03-31 | $0.17 | |||
| 2008-12-31 | 2008-12-31 | $0.21 | |||
| 2008-06-30 | 2008-06-30 | $0.23 | |||
| 2008-03-31 | 2008-03-31 | $0.24 | |||
| 2007-12-31 | 2007-12-31 | $0.21 | |||
| 2005-06-30 | 2005-06-30 | $0.13 | |||
| 2005-03-31 | 2005-03-31 | $0.12 | |||
| 2004-12-31 | 2004-12-31 | $0.13 |
Carl Zeiss Meditec AG (CZMWF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Research Development | 54.2 million | N/A | 53.11 million | 53.11 million | 53.63 million |
| Income Before Tax | 66.6 million | N/A | 5.9 million | 5.9 million | 40.23 million |
| Selling General Administrative | 82.1 million | N/A | 75.16 million | 75.16 million | 92.14 million |
| Gross Profit | 207.3 million | N/A | 137.67 million | 137.67 million | 191.47 million |
| Ebit | 68.4 million | N/A | 8.97 million | 8.97 million | 43.15 million |
| Operating Income | 73.4 million | N/A | 9.4 million | 9.4 million | 45.7 million |
| Income Tax Expense | N/A | 21.9 million | N/A | 2.34 million | N/A |
| Total Revenue | 368.9 million | N/A | 252.97 million | 252.97 million | 345.26 million |
| Cost of Revenue | 161.6 million | N/A | 115.31 million | 115.31 million | 153.79 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | N/A |
| Net Income From Continuing Operations | 46.3 million | N/A | 3.56 million | 3.56 million | 26.5 million |
| Net Income Applicable to Common Shares | N/A | 53.19 million | N/A | 5.29 million | N/A |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | -8.62 million | -8.62 million |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Operating Activities | N/A | N/A | N/A | N/A | N/A |
| Change in Cash | N/A | N/A | N/A | N/A | N/A |
| Total Cash from Operating Activities | N/A | N/A | N/A | 14.32 million | 14.32 million |
| Depreciation | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 601.12 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 1.46 billion |
| Other Current Liabilities | N/A | 91.01 million | N/A | N/A | 30.01 million |
| Total Assets | N/A | N/A | N/A | N/A | 2.08 billion |
| Common Stock | N/A | 89.44 million | N/A | N/A | N/A |
| Other Current Assets | N/A | 21.49 million | N/A | N/A | 21.37 million |
| Retained Earnings | N/A | 808.92 million | N/A | N/A | 808.58 million |
| Other Liabilities | N/A | 212.05 million | N/A | N/A | N/A |
| Other Assets | N/A | 109.99 million | N/A | N/A | N/A |
| Cash | N/A | N/A | N/A | N/A | 14.95 million |
| Total Current Liabilities | N/A | 297.58 million | N/A | N/A | 335.44 million |
| Other Stockholder Equity | N/A | -86.78 million | N/A | N/A | N/A |
| Property, Plant & Equipment | N/A | 135.27 million | N/A | N/A | N/A |
| Total Current Assets | N/A | 1.29 billion | N/A | N/A | 1.36 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 1.08 billion | 960.55 million | 975.65 million | 975.65 million | N/A |
| Short Term Investments | N/A | N/A | N/A | N/A | 13.82 million |
| Long Term Debt | N/A | N/A | N/A | N/A | 110.13 million |
| Inventory | N/A | 286.36 million | N/A | N/A | 317.43 million |
| Accounts Payable | N/A | 91.68 million | N/A | N/A | 117.21 million |
Carl Zeiss Meditec AG (CZMWF) Chart:
Carl Zeiss Meditec AG (CZMWF) News:
Below you will find a list of latest news for Carl Zeiss Meditec AG (CZMWF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Carl Zeiss Meditec AG (CZMWF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Carl Zeiss Meditec AG (CZMWF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|